广电电气：全资子公司拟出售参股公司股权 5月27日晚，广电电气（601616）发布公告称，全资子公司上海广电电气集团投资管理有限公司拟将其 持有的参股公司上海赢双电机科技股份有限公司5.91%的股权转让给亚普汽车部件股份有限公司，交易 对价为6263.32万元。此次交易完成后，公司仍持有赢双科技2.9974%的股权。该交易旨在优化公司资产 结构。 资料显示，广电电气成立于1995年12月，主营业务是配电与控制设备的研发、制造、销售及服务。 所属行业：电力设备–电网设备–配电设备 皖天然气：超短期融资券和中期票据获准注册 5月27日晚，皖天然气（603689）发布公告称，公司近日收到中国银行间市场交易商协会出具的《接受 注册通知书》，同意公司注册发行超短期融资券和中期票据。超短期融资券注册金额为5亿元，中期票 据注册金额为6亿元，注册额度有效期均为2年。公司将在规定期限内择机发行。 资料显示，皖天然气成立于2003年2月，主营业务是安徽省内天然气长输管线的投资、建设和运营、销 售贸易、城市燃气、设施安装以及综合能源等业务。 所属行业：公用事业–燃气Ⅱ–燃气Ⅲ 华润双鹤：全资子公司安徽双鹤药业通过GMP符合性检查 ...

Group 1 - Company Zhongnan Media signed a government procurement contract worth 1.009 billion yuan for the supply of free textbooks and related teaching resources in Hunan Province for 2025, ensuring stable revenue for the company [1] - Company Zhongnan Media was established in December 2008, focusing on the publishing, distribution, and printing of publications [2] Group 2 - Company Tongling Nonferrous Metals announced the resignation of its general manager and deputy general manager due to higher-level assignments [3] - Company Tongling Nonferrous Metals was founded in November 1996, primarily engaged in the mining and processing of copper, iron, and sulfur gold [4] Group 3 - Company Xinyi Co. plans to reduce its shareholding by no more than 1% due to personal asset allocation needs [5] - Company Xinyi Co. was established in April 1996, specializing in the research, production, and sales of functional new materials based on organic synthetic resins [6] Group 4 - Company Xinhua Pharmaceutical received approval for the registration of ibuprofen suspension drops, a non-prescription drug for relieving fever and mild to moderate pain in children [7] - Company Xinhua Pharmaceutical was founded in November 1998, focusing on the sales of raw materials and intermediates, as well as chemical products [8] Group 5 - Company Emei Mountain A elected Tong Jianming as a director and appointed him as the general manager [9] - Company Emei Mountain A was established in October 1997, primarily engaged in tourism services, including ticket sales and hotel operations [10] Group 6 - Company Heng Rui Medicine announced the approval of its innovative drug, Regaglitin Metformin tablets, for market launch, aimed at improving blood sugar control in type 2 diabetes patients [11] - Company Heng Rui Medicine was founded in April 1997, focusing on the research, production, and sales of pharmaceuticals [12] Group 7 - Company Chongqing Rural Commercial Bank announced the approval of Tang Li's qualification as vice president [13] - Company Chongqing Rural Commercial Bank was established in June 2008, focusing on inclusive finance and corporate financial services [14] Group 8 - Company Weili Medical received certification from the Canadian Ministry of Health for its extraction bag, allowing legal sales in the Canadian market [15] - Company Weili Medical was founded in April 2004, specializing in the research, production, and sales of medical devices in various fields [16] Group 9 - Company Ailis received approval for its KRAS G12C inhibitor, a new drug for treating advanced non-small cell lung cancer [17] - Company Ailis was established in March 2004, focusing on innovative drug research and development in oncology [18] Group 10 - Company Renfu Pharmaceutical received registration certificates for two new drugs, including methylprednisolone tablets and hydrocodone ibuprofen tablets [19] - Company Renfu Pharmaceutical was founded in March 1993, focusing on the research, production, and sales of pharmaceuticals [20] Group 11 - Company Siwei Tuxin received multiple invention patent certificates from the National Intellectual Property Administration [21] - Company Siwei Tuxin was established in December 2002, focusing on navigation maps, intelligent driving, and automotive electronic chips [22] Group 12 - Company Changhong High-Tech received a warning letter from the Ningbo Securities Regulatory Bureau for failing to disclose related party transactions [23] - Company Changhong High-Tech was founded in June 2012, focusing on the research, production, and sales of styrene thermoplastic elastomers [24] Group 13 - Company Gansu Energy Chemical announced the resignation of its director and general counsel due to organizational adjustments [25] - Company Gansu Energy Chemical was established in December 1996, focusing on coal mining and sales [26] Group 14 - Company Shanghai Construction received land use rights for a residential project in Tianjin, with a total investment of approximately 330 million yuan [27] - Company Shanghai Construction was founded in June 1998, focusing on construction, design consulting, and real estate development [28] Group 15 - Company Chengdu Xian Dao announced that a major shareholder plans to increase its stake in the company by 25 to 50 million yuan [29] - Company Chengdu Xian Dao was established in February 2012, focusing on drug research and development services [30] Group 16 - Company Hunan Silver announced the resignation of its deputy general manager due to organizational adjustments [31] - Company Hunan Silver was founded in November 2004, focusing on the smelting and sales of silver and other precious metals [32] Group 17 - Company China Chemical reported a total contract amount of 123.017 billion yuan for the first four months of the year [33] - Company China Chemical was established in September 2008, focusing on construction engineering and modern services [34] Group 18 - Company Borui Pharmaceutical received a registration certificate for iodinated contrast agent injection [35] - Company Borui Pharmaceutical was founded in October 2001, focusing on the research and production of pharmaceutical intermediates and raw materials [36] Group 19 - Company Wanhua Chemical announced a technical transformation of its ethylene unit, aiming to diversify raw materials and enhance competitiveness [37] - Company Wanhua Chemical was established in December 1998, focusing on the research, production, and sales of polyurethane and fine chemicals [38] Group 20 - Company ST Houlv received approval for its injectable cephalosporin sodium to pass the consistency evaluation for generic drugs [39] - Company ST Houlv was founded in June 2005, focusing on drug research, production, and sales [40] Group 21 - Company Anka Intelligent announced a targeted reduction of capital for its subsidiary [41] - Company Anka Intelligent was established in May 2004, focusing on the research and development of power system solutions [42] Group 22 - Company Huaming Intelligent announced financial support for its subsidiary [43] - Company Huaming Intelligent was founded in August 2001, focusing on intelligent systems and services [44] Group 23 - Company Foton Motor received a central subsidy of 124 million yuan for promoting new energy vehicles [45] - Company Foton Motor was established in August 1996, focusing on vehicles and mobile equipment [46] Group 24 - Company Guangsheng Tang received a registration certificate for ritonavir tablets, used in HIV treatment [47] - Company Guangsheng Tang was founded in June 2001, focusing on the research and production of antiviral drugs [48] Group 25 - Company Kexing Pharmaceutical received FDA approval for clinical trials of its GB18 injection in the United States [49] - Company Kexing Pharmaceutical was established in August 1997, focusing on the research and production of recombinant protein drugs [50] Group 26 - Company Heng Rui Medicine announced the final price for its H-share public offering at 44.05 HKD per share [51] - Company Heng Rui Medicine was founded in April 1997, focusing on the research, production, and sales of pharmaceuticals [52] Group 27 - Company Wandong Medical elected a new chairman following the resignation of the previous chairman [53] - Company Wandong Medical was established in May 1997, focusing on the research, production, and sales of medical imaging equipment [54] Group 28 - Company Qixia Construction announced a plan to reduce its shareholding by no more than 3% [55] - Company Qixia Construction was founded in December 1999, focusing on real estate development and management [56] Group 29 - Company Dasheng Intelligent signed a contract worth 11.5 million yuan for a high-efficiency machine room project [57] - Company Dasheng Intelligent was established in March 1995, focusing on AIoT intelligent management platforms [58] Group 30 - Company Huashi Technology announced an extension of the detention period for its actual controller [59] - Company Huashi Technology was founded in June 1998, focusing on information system integration and technical services [60] Group 31 - Company Tianzhihang announced plans to increase capital for its subsidiary [61] - Company Tianzhihang was established in October 2010, focusing on orthopedic surgical navigation robots [62] Group 32 - Company Pingzhi Information signed a procurement framework agreement with China Mobile for base station antennas [63] - Company Pingzhi Information was founded in November 2002, focusing on communication equipment and services [64] Group 33 - Company Mengke Pharmaceutical received acceptance for its new drug application for a new antibacterial drug [65] - Company Mengke Pharmaceutical was established in August 2012, focusing on small molecule drug research [66] Group 34 - Company Kede Education announced a change in its actual controller to a state-owned asset supervision committee [67] - Company Kede Education was founded in January 2003, focusing on education services [68] Group 35 - Company Jinlong Automobile elected a new chairman following the board meeting [69] - Company Jinlong Automobile was established in October 1996, focusing on the production and sales of buses [70] Group 36 - Company Jushen Co. received dividends totaling 95.7 million yuan from its subsidiaries [71] - Company Jushen Co. was founded in November 2011, focusing on logistics and warehousing services [72] Group 37 - Company Qingyun Technology announced plans for shareholders to reduce their holdings by up to 4.5% [73] - Company Qingyun Technology was established in April 2012, focusing on cloud computing products and services [74] Group 38 - Company Shengdexintai received a procurement notice from Dongfang Electric for a project worth 234 million yuan [75] - Company Shengdexintai was founded in October 2001, focusing on the production and sales of energy equipment [76] Group 39 - Company Juzhi Technology announced a plan for a director to reduce his holdings by up to 400,000 shares [77] - Company Juzhi Technology was established in November 2007, focusing on machine vision equipment [78] Group 40 - Company Sanrenxing announced plans for shareholders to reduce their holdings by up to 3% [79] - Company Sanrenxing was founded in August 2003, focusing on integrated marketing services [80] Group 41 - Company Transsion Holdings announced plans to increase capital for its subsidiary by 70 million yuan [81] - Company Transsion Holdings was established in August 2013, focusing on smart terminal design and sales [82] Group 42 - Company Jinling Pharmaceutical received approval for its raw material drug for iron deficiency anemia [83] - Company Jinling Pharmaceutical was founded in September 1998, focusing on drug manufacturing and healthcare services [84] Group 43 - Company Xiyu Tourism announced plans for shareholders to reduce their holdings by up to 3% [85] - Company Xiyu Tourism was established in January 2001, focusing on tourism and scenic area management [86]

证券研究报告 | 行业周报 gszqdatemark 2025 05 17 年 月 日 医药生物 【周专题&周观点】【总第 397 期】肿瘤恶病质有哪些潜力药物在研? 一、当周（5.12-5.16）回顾与周专题： 当周（5.12-5.16）申万医药指数环比+1.27%，跑输创业板指数，跑赢沪深 300 指数。本周周报， 我们对肿瘤恶病质的发病机制、在研药物进行了梳理，建议重点关注长春高新（美适亚、GS3-007a）、 科兴制药（GB18）、阳光诺和（STC008）、石药集团（JMT203）、劲方医药（GFS202A）等。 二、近期复盘： 1、当周表现：本周市场冲高回落走倒 V 字，医药指数震荡向上，细分上本周表现亮眼的不多，仿 创 Pharma 走的比较强，AI 也表现了一下，其他主题条线如麦角硫因、原料药涨价、新冠等都有 一定表现。创新药周五尝试反攻。 2、原因分析：本周市场表现主要是受关税缓和影响，医药这边有一定扰动的事情是特朗普降药价 政策，影响到了美股医药进而对国内创新药产生了情绪性冲击，其他行业性大事件不多。本周前期 强势的创新药还在调整消化期，市场对创新药的产业逻辑认可度提升不小，虽然前期强势创新 ...

经过20 多年的发展，公司已经将人口过亿、GDP 排名前三十的新兴市场国家全部覆盖。2024 年位于济 南的白蛋白紫杉醇生产线获得了欧洲药品管理局GMP 证书、欧盟委员会上市批准，并于次月开始在欧 盟、英国法规市场销售。截止至2024 年底，公司引进了16 款产品，已在 60 余个国家提交了 120 多项注 册申请；白蛋白紫杉醇、英夫利西单抗、贝伐珠单抗、利拉鲁肽等产品2025 年将陆续在多个国家、地 区获批注册，实现上市销售。我们认为，随着白蛋白紫杉醇开始销售，以及2025 年更多产品在海外注 册/销售，公司海外市场销售值得期待。 创新药平台重估：截止至2024 年底，公司已经构建了领先的重组蛋白药物、抗体药物、递送系统技 术、微生态制剂研发及产业化、载体疫苗等五大技术平台，已经成功研发2 个III 期临床资产、2 个早期 临床资产。其中，人干扰素α1b 吸入溶液国内处于III 期，同时取得了美国临床许可；聚乙二醇化人粒 细胞刺激因子注射液处于III 期；GB18中国药监局已受理IND 申请 ，美国处于Pre-IND 阶段。 投资建议 我们认为，公司2024 年已经实现扭亏为盈，海外商业化处于快速兑现阶段， ...

公司报告 | 季报点评 科兴制药（688136） 证券研究报告 2025Q1 海外收入持续增长，创新平台进入收获期 事件 近日，公司发布 2024 年年报和 2025 年第一季度报告。公司 2024 年全年 营业收入为 14.07 亿元，同比增长 11.75%，归母净利润为 0.31 亿元，同比 增长 116.54%。2025 年第一季度，公司实现营业收入 3.54 亿元，同比下降 1.97%，外销收入增长 84.33%，归母净利润为 2558 万元，同比增长 106%。 创新平台渐入收获期，靶点创新度大，具有出海潜力 公司针对 GDF-15 靶点候选在研药物 GB18 关于治疗肿瘤恶病质的临床试 验已经获得 NMPA 受理。已正式发表的临床前研究数据显示其在恶病质小 鼠模型上可以有效地缓解体重减轻情况并恢复身体机能。根据 WHO 数据 显示，2022 年全球新发肿癌症病例数 2000 万，约半数患者为晚期，其中 50-80%的患者受到恶病质影响，约 900 万目标患者，市场空间大。 GDF-15 靶点在研药物的肿瘤恶病质适应症已 POC，临床获益初步确认。 目前辉瑞制药的 Ponsegromab 于 ESM ...

公司报告 | 季报点评 科兴制药（688136） 证券研究报告 2025Q1 海外收入持续增长，创新平台进入收获期 2024 年海外收入 2.24 亿元，同比增长约 61.96%。根据股权激励，2025 年 海外收入相较 2023 年的目标增速为 200%-400%，预计为 4.15-6.92 亿元。 科兴制药海外销售渠道已经覆盖七十多个国家和地区，在巴西、墨西哥、 新加坡、德国、越南、埃及等地设立了子公司，覆盖欧州、中南美、东南 亚、中东北非等区域。目前已引进 10 余款重磅药物的海外商业化权益， 近期，引进的产品阿达木单抗和贝伐珠单抗已分别获得沙特和巴西等地的 GMP 证书。公司于 2024 年引进的九源基因的司美格鲁肽生物类似物，其 有望于 2025 年在国内获批上市，科兴制药已同步开展海外上市准入的准 备工作，预计于 2025 年向巴西 ANVISA 递交 NDA。近期，公司与科伦药 业、海创药业等公司签署战略合作，进一步扩大公司海外业务拓展基础。 事件 近日，公司发布 2024 年年报和 2025 年第一季度报告。公司 2024 年全年 营业收入为 14.07 亿元，同比增长 11.75%，归母净利 ...

[Table_StockNameRptType] 科兴制药（688136） 公司点评 新兴市场出海策略收获，一季度海外增利显著 -50% 0% 50% 100% 150% 200% 科兴制药 沪深300 分析师：谭国超 执业证书号：S0010521120002 邮箱：tangc@hazq.com 联系人：任婉莹 执业证书号：S0010123060034 邮箱：renwanying@hazq.com [相关报告 Table_CompanyReport] 1.【华安医药】科兴制药（688136.SH） 公司深度：重组蛋白业务稳健增长，出 口海外未来可期 2023-12-06 2.【华安医药】公司点评科兴制药 （688136.SH）：24Q1 扭亏为盈，海 外重组蛋白业务即将收获 2024-4-30 | | | | 报告日期： | 2025-04-28 | | | --- | --- | --- | | [Table_BaseData] 收盘价（元） | | 38.23 | | 近 12 个月最高/最低（元） | 42.10/13.67 | | | 总股本（百万股） | | 200 | | 流通股本（百万股） | ...